Lena Dixit, MD
Ophthalmology · Round Rock, TXNPI 1174816433
Payments from drug & device makers
Across 243 payments — averaging $151.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$20K
- Ocular Therapeutix, Inc.$11K
- Alcon$1K
- AbbVie$875
- Johnson & Johnson Surgical Vision, Inc.$749
- Sun Pharmaceutical Industries Inc.$740
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,02515%
- Speaking & faculty fees$260%
- Travel & lodging$120%
- Food & beverage$5,76084%
- Gifts$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 19 | $20,329 |
| Ocular Therapeutix, Inc. | 8 | $10,684 |
| Alcon | 38 | $1,037 |
| AbbVie(2 entities) | 32 | $875 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $749 |
| Sun Pharmaceutical Industries Inc. | 27 | $740 |
| Biotissue Holdings Inc. | 8 | $252 |
| Harrow Eye, LLC | 8 | $229 |
| Apellis Pharmaceuticals, Inc. | 5 | $227 |
| Bausch & Lomb Americas Inc. | 10 | $190 |
| Astellas Pharma US Inc | 8 | $152 |
| Amgen | 1 | $124 |
| Aerie Pharmaceuticals, Inc. | 7 | $123 |
| Optovue, Inc. | 1 | $100 |
| Novartis | 5 | $99 |
| Carl Zeiss Meditec USA, Inc. | 2 | $98 |
| Genentech USA, Inc. | 4 | $94 |
| Dompe US, Inc. | 5 | $93 |
| Oyster Point Pharma, Inc. | 6 | $93 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Shire North American Group Inc | 5 | $74 |
| Tarsus Pharmaceuticals, Inc. | 3 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $60 |
| Eyevance Pharmaceuticals LLC | 3 | $48 |
| Iridex Corporation | 1 | $46 |
| Sight Sciences, Inc. | 2 | $44 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Optos, Inc. | 1 | $23 |
| Omeros Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$1,800
- Tecnis Symfony IOL$375
- PanOptix$134
- TEPEZZA$124
- ReSTOR$120
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$104
- XR$100
How this compares
$36,858 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 44 | $60,153 |
| LumiganBimatoprost | 48 | $31,492 |
| XiidraLifitegrast | 17 | $24,331 |
| Cyclosporine | 19 | $19,625 |
| RhopressaNetarsudil Mesylate | 38 | $15,911 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,827 |
| CequaCyclosporine | 18 | $11,142 |
| Prednisolone Acetate | 187 | $9,630 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $8,817 |
| Fluorometholone | 90 | $8,196 |
| VevyeCyclosporine | 11 | $7,676 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $7,068 |
| Brimonidine Tartrate | 106 | $6,832 |
| ZirganGanciclovir | 12 | $5,846 |
| Latanoprost | 406 | $5,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $875 | $97,338103 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan | $190 | $43,00446 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $123 | $24,72856 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $740 | $11,14218 claims |
| Harrow Eye, LLCVevye | $229 | $7,67611 claims |
| AlconSimbrinza | $1,037 | $7,06826 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $60 | $3,04818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Round Rock
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.